Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Posted by on Jul 21st, 2026

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $69.1667.

ELVN has been the topic of a number of recent analyst reports. The Goldman Sachs Group upped their price target on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Mizuho lifted their price objective on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday. Guggenheim began coverage on Enliven Therapeutics in a research report on Tuesday, May 12th. They issued a “buy” rating and a $80.00 target price on the stock. Finally, Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th.

Get Our Latest Stock Analysis on ELVN

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40. Following the completion of the transaction, the chief financial officer owned 51,000 shares in the company, valued at approximately $2,233,800. This trade represents a 10.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the transaction, the director directly owned 51,884 shares of the company’s stock, valued at $1,792,073.36. The trade was a 16.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 26,018 shares of company stock valued at $1,113,888. 3.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

Several institutional investors have recently modified their holdings of ELVN. Commodore Capital LP increased its stake in Enliven Therapeutics by 0.4% during the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after buying an additional 17,809 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after acquiring an additional 2,670,000 shares in the last quarter. Polar Capital Holdings Plc boosted its stake in shares of Enliven Therapeutics by 13.5% in the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after acquiring an additional 418,673 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Enliven Therapeutics by 5.9% in the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after acquiring an additional 142,378 shares during the last quarter. Finally, State Street Corp increased its position in shares of Enliven Therapeutics by 9.1% during the fourth quarter. State Street Corp now owns 1,052,862 shares of the company’s stock worth $16,214,000 after purchasing an additional 87,725 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Trading Down 2.9%

Shares of NASDAQ ELVN opened at $51.67 on Tuesday. The stock has a market capitalization of $3.15 billion, a PE ratio of -30.94 and a beta of 0.24. The stock’s fifty day simple moving average is $44.64 and its two-hundred day simple moving average is $36.36. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $54.10.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. On average, equities analysts predict that Enliven Therapeutics will post -1.57 earnings per share for the current fiscal year.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

Featured Stories

Analyst Recommendations for Enliven Therapeutics (NASDAQ:ELVN)

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.